Publications / Presentations
Neuropsychiatry / Neurology
Publications
- Journal of Neurology and Neuromedicine 2018, 3(5):39-50 (Invited Review).
Brilaroxazine (RP5063) Clinical Experience in Schizophrenia: A New Option to Address Unmet Needs.
Laxminarayan Bhat, Marc Cantillon, and Robert Ings
- European Journal of Drug Metabolism and Pharmacokinetics 2018, 43:573-585.
Marc Cantillon, Robert Ings, Arul Prakash, Laxminarayan Bhat
- Clinical and Translational Science 2018, 11:387-396.
Marc Cantillon, Robert Ings, and Laxminarayan Bhat
- Clinical and Translational Science 2018, 11:378-386.
Marc Cantillon, Robert Ings, and Laxminarayan Bhat
- Schizophrenia Research 2017, 189: 126-133.
Marc Cantillon, Arulprakash R, Ajay Alexander, Robert Ings, Dennis Sweitzer, Laxminarayan Bhat
- Behavioral Brain Research 2017, 332: 180-199.
Lakshmi Rajagopal, Sunoh Kwon, Mei Huang, Eric Michael, Laxminaryan Bhat, Marc Cantillon, Herbert Y. Meltzer
Presentations
- Society for Neuroscience Annual Meeting, Chicago, USA. October 17-21, 2015
RP5063 reverses and prevents subchronic phencyclidine-induced declarative memory deficits and increases cortical dopamine in C57BL/6J mice.
Kwon S. et al.
- New Clinical Drug Evaluation Unit (NCDEU) Conference, Hollywood, Florida, USA. May 29, 2013.
RP5063 safety and efficacy in schizophrenia and schizoaffective disorder.
Cantillon M. et al.
- New Clinical Drug Evaluation Unit (NCDEU) Conference, Phoenix, Arizona, USA. May 30, 2012.
RP5063 safety, pharmacokinetics and pharmacodynamics in schizophrenia.
Cantillon M. et al.
Vascular / Pulmonary Diseases
Publications
- Journal of Genetic Syndromes & Gene Therapy 2018, 9:43.
Laxminarayan Bhat.
- Journal of Genetic Syndromes & Gene Therapy 2018, 9:36.
Laxminarayan Bhat.
- European J Pharmacology 2018, 827:159-166.
Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.
- Biomedical Advances in Cardiovascular Disease 2018 Feb (Invited Synopsis)
RP5063 is effective in sugen-hypoxia-induced pulmonary arterial hypertension in rats.
Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.
- Journal of Rare Disease Research & Treatment 2017, 2(5): 5-12 (Invited Review)
A closure look at the preclinical experience of RP5063 in pulmonary arterial hypertension (PAH).
Laxminarayan Bhat and Dany Salvail.
- European J Pharmacology 2017, 810: 83-91.
Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.
- European J Pharmacology 2017, 810: 92-99.
Laxminarayan Bhat, Jon Hawkinson, Marc Cantillon, Dasharatha G Reddy, Seema R Bhat, Charles E. Laurent, Annie Bouchard, Marzena Biernat, and Dany Salvail.
Presentations
- American Thoracic Society (ATS) International Conference, Washington DC, USA. May 19-24, 2017.
RP5063 mitigates the developments and severity of sugen-hypoxia induced pulmonary arterial hypertension in rats.
Bhat L. et al.
- American Thoracic Society (ATS) International Conference, San Francisco, USA. May 13-18, 2016
RP5063 prevents moncrotaline-induced pulmonary arterial hypertension in rats.
Bhat L. et al.